Unlock instant, AI-driven research and patent intelligence for your innovation.

Febuxostat imidazolium salt hydrate, and preparation method and application thereof

A technology of febuxostat salt and febuxostat, which is applied in the field of new drug salt forms, can solve the problems of reducing febuxostat bioavailability, affecting absorption, low water solubility of febuxostat, etc., and achieving rapid thermodynamics Stability, rapid dissolution, high crystallinity effect

Inactive Publication Date: 2018-11-23
WUZHOU UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the low water solubility of febuxostat, it affects its absorption in the body and reduces the bioavailability of febuxostat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Febuxostat imidazolium salt hydrate, and preparation method and application thereof
  • Febuxostat imidazolium salt hydrate, and preparation method and application thereof
  • Febuxostat imidazolium salt hydrate, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Step 1: Dissolve 40.00 mg of febuxostat and 20.00 mg of imidazole in 5 mL of saturated ethyl acetate aqueous solution, heat and stir for 0.5 h to obtain a saturated solution;

[0041] Step 2: Place the saturated solution obtained in step 1 in an environment of 0-35°C, let it stand, transfer the supernatant liquid to a glass test tube, seal the test tube opening with a parafilm, and pierce the parafilm with a needle for 2-4 After 15 days, colorless and transparent massive crystals began to separate out, and were filtered to obtain crystals;

[0042] Step 3: Place the crystal obtained in Step 2 in a vacuum oven at 60-70°C for 24 hours to obtain it. It is determined by single crystal diffraction to be febuxostat imidazolate hydrate, as shown in Figure 1-2 Shown; Compare the crystallographic data of febuxostat and febuxostat imidazolium salt hydrate, see Table 1 for details:

[0043] The crystallographic data comparison of febuxostat and febuxostat imidazolium salt hydrat...

Embodiment 2

[0047] Step 1: Dissolve 40.00 mg of febuxostat and 20.00 mg of imidazole in 5 mL of ethyl acetate, heat and stir for 1 hour to obtain a saturated solution;

[0048] Step 2: Place the saturated solution obtained in step 1 in an environment of 0-35°C, let it stand, transfer the supernatant liquid to a glass test tube, seal the test tube opening with a parafilm, and pierce the parafilm with a needle for 2-4 After 15 days, colorless and transparent massive crystals began to separate out, and were filtered to obtain crystals;

[0049] Step 3: Put the crystal obtained in Step 2 in a vacuum drying oven at 60-70°C for 24 hours to obtain.

Embodiment 3

[0051] Step 1: Dissolve 5.0 g of febuxostat and 2.00 g of imidazole in 50 mL of saturated ethyl acetate aqueous solution, heat and stir for 1 hour to obtain a saturated solution;

[0052] Step 2: Place the saturated solution obtained in step 1 in an environment of 0-35°C, let it stand, transfer the supernatant liquid to a glass test tube, seal the test tube opening with a parafilm, and pierce the parafilm with a needle for 2-4 After 20 days, colorless and transparent massive crystals began to separate out, and were filtered to obtain crystals;

[0053] Step 3: Place the crystal obtained in Step 2 in a vacuum oven at 60-70°C for 24 hours to obtain it. It is determined by XRD powder diffraction to be febuxostat imidazolate hydrate, as shown in image 3 , 4 and 5.

[0054] in, image 3 Among them, a refers to the actual PXRD pattern of imidazole, b refers to the actual PXRD pattern of febuxostat imidazole salt hydrate, c refers to the actual PXRD pattern of febuxostat imidazole ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses febuxostat imidazolium salt hydrate, and a preparation method and application thereof, and relates to the field of new salt types of drugs. The invention aims at providing febuxostat imidazolium salt hydrate with high water solubility and good safety. The febuxostat imidazolium salt hydrate is formed by adopting N-H ellipsis O bonds for an asymmetric structure unit consisting of a protonated imidazole, a deprotonated febuxostat and a water molecule, and has a two-dimensional meshed space structure, and the space group is a triclinic P-1 crystal system; crystallographicdata is as follows: in bond lengths, a is equal to 9.0058(8), b is equal to 10.3017(7) and c is equal to 13.0092(11); in bond angles, alpha is equal to 67.157(7) degrees, beta is equal to 82.211(7) degrees, gamma is equal to 65.204(8) degrees; Z is equal to 2, and V is equal to 1009.19(14).

Description

technical field [0001] The invention relates to the field of new salt forms of medicines, in particular to a febuxostat imidazolium salt hydrate and a preparation method and application thereof. Background technique [0002] According to statistics, about 70-80% of drug candidates are poorly soluble drugs with very low solubility, and this characteristic usually limits the bioavailability of poorly soluble drugs, resulting in poor therapeutic effects of poorly soluble drugs. At present, there are many methods to improve the water solubility of poorly soluble drugs, such as micronization, nanocrystals, self-emulsification, solid dispersants, phospholipid complexes, cyclodextrin inclusion complexes, co-crystals and salt formation, etc. effect is most pronounced. [0003] Febuxostat is the latest selective xanthine oxidase inhibitor, which was approved by the US FDA in 2009. It is the only xanthine oxidase with a non-purine structure approved by the US FDA for the treatment of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D277/56C07D233/06A61P19/06
CPCA61P19/06C07B2200/13C07D233/06C07D277/56
Inventor 张宪瑞王雨晴邹心怡廖周林高蕾
Owner WUZHOU UNIV